Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Fineline Cube Sep 9, 2026
Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Fineline Cube Sep 9, 2026
Company Legal / IP

Beijing Intellectual Property Court Upholds Validity of Novartis’ Entresto Patent

Fineline Cube Jul 21, 2023

The Beijing Intellectual Property Court (BIPC) has issued a judgment that reaffirms the validity and...

Company Drug

Johnson & Johnson Reports 7.5% YOY Sales Growth in Q2 2023, Driven by Pharma and Devices

Fineline Cube Jul 21, 2023

Johnson & Johnson (J&J; NYSE: JNJ) has published its financial results for the second quarter...

Company

Sartorius Expands Global Footprint with New Cell Culture Facility in Puerto Rico

Fineline Cube Jul 21, 2023

Germany-based laboratory services firm Sartorius has expanded its operations with the opening of a new...

Company

Sandoz Plans USD 90 Million Biosimilar Development Center in Slovenia by 2026

Fineline Cube Jul 21, 2023

The Sandoz unit of Switzerland-based Novartis (NYSE: NVS) has announced plans to construct a biosimilar...

Company Deals Policy / Regulatory

Johnson & Johnson Files Lawsuit Against US Government’s Drug Pricing Negotiation Authority

Fineline Cube Jul 21, 2023

United States-based Johnson & Johnson (J&J, NYSE: JNJ) has filed a lawsuit this week, challenging...

Company Deals

GSK Partners with LimmaTech for Further Development of Quadrivalent Shigellosis Vaccine

Fineline Cube Jul 21, 2023

UK-based pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has licensed its quadrivalent bioconjugate shigellosis vaccine candidate...

Company

Abbott Reports Q2 2023 Revenue Growth Exceeding Estimates Despite COVID-19 Dip

Fineline Cube Jul 21, 2023

US-based life sciences firm Abbott (NYSE: ABT) has released its financial results for the second...

Company Drug

Jiangsu Simcere Pharmaceutical Gets NMPA Approval for Quviviq, Anti-Insomnia Drug

Fineline Cube Jul 21, 2023

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced the receipt of clinical trial approval...

Company Deals

Livzon Pharmaceutical Secures Licensing Agreement for Synergy Pharma’s HHT120 in Greater China

Fineline Cube Jul 21, 2023

China-based Livzon Pharmaceutical Group Inc. (HKG: 1513) has announced a licensing agreement with fellow Chinese...

Company Deals Digital

Alibaba Health and Daiichi Sankyo Partner to Innovate in Digital Healthcare Services

Fineline Cube Jul 20, 2023

China’s Alibaba Health Information Technology Ltd (HKG: 0241) has entered into a strategic partnership with...

Drug

Pfizer’s GBS Vaccine Candidate GBS6 Shows Promise in Phase II Maternal Immunization Study

Fineline Cube Jul 20, 2023

Pfizer (NYSE: PFE) has this week published the Phase II data for its Group B...

Legal / IP Policy / Regulatory

US Merger Guidelines Updated: Public Comment Sought on Antitrust Law Changes

Fineline Cube Jul 20, 2023

The United States has published an update to its merger and acquisition guidelines, seeking public...

Company Drug

Merck and Telix Pharmaceuticals Initiate Phase I Study for CAIX-Expressing Tumors Therapy

Fineline Cube Jul 20, 2023

A Phase I study assessing the combination of German-major Merck’s (NYSE: MRK) DNA-PK inhibitor, peposertib,...

Company Drug

Janssen’s Sirturo (Bedaquiline) Expands Indication to Include Adolescents with MDR-TB

Fineline Cube Jul 20, 2023

The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced that the National...

Company Drug

Chongqing Zhifei Biological Launches Phase I Clinical Trial for Group B Meningococcal Vaccine

Fineline Cube Jul 20, 2023

Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the commencement of a Phase I...

Company Drug

Chipscreen Pharmaceutical’s Epidaza Granted Priority Status for DLBCL Treatment in China

Fineline Cube Jul 20, 2023

The Center for Drug Evaluation (CDE) website has announced that Shenzhen Chipscreen Biosciences Co., Ltd’s...

Company Drug

HutchMed’s Elunate-Tyvyt Combo Receives Breakthrough Therapy Designation in China for Endometrial Cancer

Fineline Cube Jul 20, 2023

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) has announced that the combination of Elunate (fruquintinib)...

Company Drug

Kintor Pharmaceutical Initiates Long-Term Safety Trial for Androgenetic Alopecia Treatment KX-826

Fineline Cube Jul 20, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the start of the long-term safety trial...

Company Deals

Hybribio Ltd and United Imaging Healthcare Form Strategic Partnership to Advance Medical Technology

Fineline Cube Jul 20, 2023

Guangdong-based Hybribio Ltd (SHE: 300639), a leading provider of nucleic acid molecular diagnostic products, has...

Company Deals

Novomics Partners with TopGene to Expand Genomic Testing Services in China

Fineline Cube Jul 20, 2023

South Korea-based molecular diagnostics firm Novomics Co. has announced a strategic partnership with China-based Hubei...

Posts pagination

1 … 552 553 554 … 718

Recent updates

  • BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices
  • CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation
  • Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030
  • Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins
  • China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company

BD Opens Tianjin Life Health Innovation Center With Seven Clinical Training Centers – Establishing a Northern China Hub Built on an “Experience – Training – R&D” Trinity for High‑End Medical Devices

Company Drug

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Company

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Company Drug

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.